{"nctId":"NCT02231086","briefTitle":"Adjuvant HIPEC in High Risk Colon Cancer","startDateStruct":{"date":"2015-03","type":"ACTUAL"},"conditions":["Colorectal Neoplasms","Peritoneal Neoplasms"],"count":204,"armGroups":[{"label":"Standard adjuvant systemic chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard adjuvant systemic chemotherapy","Procedure: Diagnostic laparoscopy"]},{"label":"Adjuvant HIPEC (open/laparoscopic)","type":"EXPERIMENTAL","interventionNames":["Procedure: Adjuvant HIPEC (open/laparoscopic)","Drug: Standard adjuvant systemic chemotherapy","Procedure: Diagnostic laparoscopy"]}],"interventions":[{"name":"Adjuvant HIPEC (open/laparoscopic)","otherNames":["I.V. leucovorin 20 mg/m2 (maximum 40 mg)","I.V. 5-fluorouracil 400 mg/m2 (maximum 800 mg)","Intraperitoneal oxaliplatin 460 mg/m2 (maximum 920 mg)"]},{"name":"Standard adjuvant systemic chemotherapy","otherNames":["adjuvant capecitabine and oxaliplatin (CAPOX)","adjuvant 5-FU and oxaliplatin (FOLFOX)"]},{"name":"Diagnostic laparoscopy","otherNames":["Diagnostic laparoscopic surgery"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age between 18 and 75 years\n* Intention to start routine adjuvant systemic therapy\n* adequate clinical condition to undergo simultaneous HIPEC or re- laparoscopy or re-laparotomy with HIPEC within either 10 days or between week 5-8 from --primary resection\n* written informed consent\n* white blood cell count of at least 3000/mm3, platelet count of at least 100.000/mm3\n* no bleeding diathesis or coagulopathy\n* normal creatinine or creatinine clearance of at least 50 ml/min\n\nExclusion Criteria:\n\n* postoperative complications that interfere with adjuvant HIPEC within 8 weeks (i.e. persisting intra-abdominal abscess, significant fascial dehiscence, enteric fistula)\n* no intention to start routine adjuvant systemic therapy\n* liver and/or lung metastases\n* pregnant or lactating women\n* unstable or uncompensated respiratory or cardiac disease\n* serious active infections\n* other concurrent chemotherapy\n* hypersensitivity to fluorouracil, folinic acid or another substance of leucovorin or oxaliplatin\n* stomatitis, ulceration in the mouth or gastrointestinal tract.\n* severe diarrhea\n* severe hepatic and / or renal dysfunction.\n* plasma bilirubin concentrations greater than 85 Î¼mol/l.\n* pernicious anemia or other anaemias due to vitamin B12 deficiency.\n* peripheral sensory neuropathy with functional impairment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peritoneal Recurrence Free Survival at 18 Months","description":"Peritoneal recurrence-free survival at 18 months determined by CT and CEA. If CEA was normal and CT did not show any signs of peritoneal metastase at 18 months, a diagnostic laparoscopy was performed in those patients who consented to this intervention. Complete peritoneal staging was performed during laparoscopy, and biopsies were taken from suspicious lesions. If no peritoneal lesions were seen or biopsies were negative, this indicated that the patient was free from peritoneal recurrence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Related Toxicity of Adjuvant HIPEC","description":"Toxicity directly related to adjuvant HIPEC included 30-day complication rate, re-intervention rate, and re-admission rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Stay for Simultaneous and Staged HIPEC, Either Open or Laparoscopic","description":"Hospital stay for simultaneous and staged HIPEC, either open or laparoscopic.","classes":[]},{"type":"SECONDARY","title":"False-negative Rate of CT-scan for Peritoneal Metastases","description":"The presence or absence of peritoneal metastasis on CT-scan will be compared to the findings during diagnostic laparoscopy, histological biopsy or fine needle aspiration cytology.","classes":[]},{"type":"SECONDARY","title":"Patterns of Dissemination (Peritoneal Plus or Minus Distant Metastases)","description":"Patterns of dissemination (peritoneal plus or minus distant metastases).","classes":[]},{"type":"SECONDARY","title":"Disease-free Survival","description":"Disease-free survival.","classes":[]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival.","classes":[]},{"type":"SECONDARY","title":"Quality of Life Questionnaire Survey 5- Year Follow-up","description":"Quality of life questionnaire survey 5- year follow-up.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":102},"commonTop":["diarrhea","peripheral sensible neuropathy","fatigue","vomiting","mucositis"]}}}